{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:47:59Z","timestamp":1791960479031,"version":"4.3.4"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While psychedelic treatments for difficult-to-treat mental health conditions are advancing, participant perspectives remain under-explored. This study examined former participants\u2019 experiences across recruitment, preparation, dosing, integration and study ending, and generated recommendations for future trials and treatment delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This qualitative descriptive study, informed by reflexive thematic analysis, included four Psychedelic Participant Advocacy Network (PsyPAN) members who were former psychedelic-trial participants. They completed three remote focus groups on recruitment and screening, preparation and dosing, and post-dose integration and the post-study period. Three had joined treatment-resistant depression studies involving psilocybin or N,N-dimethyltryptamine; one had joined a psilocybin study for an eating disorder. A one-day workshop reviewed the analysis and developed recommendations, refined with wider PsyPAN input.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five themes were developed. First, participants entered trials seeking potentially effective treatment but encountered procedures shaped by eligibility criteria, equipoise, randomization, blinding, standardization, fixed schedules and endpoint-driven evidence generation. Second, participants\u2019 accounts extended \u201cset and setting\u201d to the clinical-trial context by showing how research-specific conditions, including treatment-allocation uncertainty, communication, staff conduct, time-limited support, study ending and the wider support matrix, shaped experience and could mitigate tensions between treatment-seeking and research requirements. Third, facilitators mediated between protocol requirements and participants\u2019 embodied, relational and psychological needs, particularly during dosing. Fourth, dosing was experienced as the beginning of an ongoing process of meaning-making, change and integration. Fifth, experiences after study ending varied; some participants described loss, grief or frustration, while all reported that further structured support would have been beneficial. They highlighted limited access to psychedelically informed care and advocated independent, trial-specific peer support. Recommendations emphasized clear communication, expectation management, distinction between research and treatment frames, reduced avoidable burden, staff continuity, participant agency, boundaries around touch and movement, involvement of support networks, and planning for integration and study ending.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Relational, contextual and systemic factors shaped participants\u2019 experiences across recruitment, preparation, dosing, integration and study ending. Participant-informed practices should be considered when designing and delivering psychedelic studies, while recognizing scientific, regulatory and resource constraints. Structured post-study peer support may address continuing support needs after trial completion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1682810","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:20:23Z","timestamp":1791958823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network"],"prefix":"10.3389","volume":"17","author":[{"given":"Mathieu","family":"Seynaeve","sequence":"first","affiliation":[{"name":"Beckley Psytech Ltd.","place":["Oxford, United Kingdom"]},{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Schneider","sequence":"additional","affiliation":[{"name":"Psychedelic Participant Advocacy Network (PsyPAN)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Roullier","sequence":"additional","affiliation":[{"name":"Psychedelic Participant Advocacy Network (PsyPAN)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Lazenby","sequence":"additional","affiliation":[{"name":"Psychedelic Participant Advocacy Network (PsyPAN)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lilley","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd.","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Lobo","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd.","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna O.","family":"Ermakova","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd.","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hattie","family":"Wells","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd.","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cleare","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Rucker","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"B1","unstructured":"World Mental Health Today. World Mental Health Report: Transforming Mental Health for All\n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"Ferrari","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00317-1","article-title":"Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021","volume":"11","author":"Santomauro","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540280071036","article-title":"The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression","volume":"277","author":"Hirschfeld","year":"1997","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/EAT.24306","article-title":"The unmet treatment need for eating disorders: What has changed in more than 10 years? An updated systematic review and meta-analysis","volume":"58","author":"Ali","year":"2025","journal-title":"Int J Eat Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/eat.24364","article-title":"The need to increase help-seeking for eating disorders in general and binge-eating disorder specifically: Commentary on Ali et\u00a0al.\u2019s (2024) meta-analysis","volume":"58","author":"Lydecker","year":"2025","journal-title":"Int J Eating Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-026-02335-z","article-title":"Psychedelic therapeutics in psychiatric conditions","author":"Harvey","year":"2026","journal-title":"Neuropsychopharmacology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ACPS.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"B9","volume-title":"Psychedelic Psychiatry. Reference Module in Neuroscience and Biobehavioral Psychology","author":"Bender","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1176\/appi.ajp.20230902","article-title":"Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research","volume":"182","author":"McIntyre","year":"2025","journal-title":"Am J Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04194-5","article-title":"The science of psychedelic medicine","volume":"32","author":"Siegel","year":"2026","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"887255","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted psychotherapy\u2014A systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front Psychol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01053-0","article-title":"Context is a critical for psychoactive drug effects","volume":"37","author":"Greenway","year":"2023","journal-title":"CNS Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1772054","article-title":"Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments","volume":"13","author":"Greenway","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2023.1200393","article-title":"Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings","volume":"17","author":"Garel","year":"2023","journal-title":"Front Hum Neurosci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-018-1625-y","article-title":"Understanding the emotions of patients with inadequate response to antidepressant treatments: Results of an international online survey in patients with major depressive disorder","volume":"18","author":"Mago","year":"2018","journal-title":"BMC Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1038\/s41598-024-53188-9","article-title":"Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study","volume":"14","author":"Breeksema","year":"2024","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMEN.0000128","article-title":"Patient experiences of treatment-resistant depression (TRD): A systematic review and qualitative meta-synthesis","volume":"1","author":"Cernat","year":"2024","journal-title":"PloS Ment Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: A history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Sci Policy Law"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1353\/PPP.2021.0032","article-title":"Containment matters: Set and setting in contemporary psychedelic psychiatry","volume":"28","author":"Noorani","year":"2021","journal-title":"Philosophy Psychiatry Psychol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/02698811251337372","article-title":"What are set and setting: Reducing vagueness to improve research and clinical practice","volume":"39","author":"Patch","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1997.10400190","article-title":"Set, setting, and matrix","volume":"29","author":"Eisner","year":"1997","journal-title":"J Psychoactive Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/S41598-023-28111-3","article-title":"From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)","volume":"15","author":"Zeifman","year":"2025","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03685-9","article-title":"An international Delphi consensus for reporting of setting in psychedelic clinical trials","volume":"31","author":"Pronovost-Morgan","year":"2025","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2024.2419662","article-title":"Beyond psychedelics: set and setting in general psychiatric practice","volume":"36","author":"Kozak","year":"2024","journal-title":"Int Rev Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/7854_2021_298","article-title":"Effects of setting on psychedelic experiences, therapies, and outcomes: A rapid scoping review of the literature","volume":"56","author":"Golden","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"B30","article-title":"Treatment recommendations Psychedelic-assisted therapy (PAT)","volume-title":"Version 1.0. Swiss Interest Group for Psychedelic-Assisted Therapy (IG PAT)","author":"Aicher","year":"2024"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPSYCHIRES.2022.10.015","article-title":"A revised and extended systematic review and meta-analysis of the relationship between childhood adversity and adult psychiatric disorder","volume":"156","author":"McKay","year":"2022","journal-title":"J Psychiatr Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/15248380221122816","article-title":"The impact of childhood psychological maltreatment on mental health outcomes in adulthood: A systematic review and meta-analysis","volume":"24","author":"Xiao","year":"2023","journal-title":"Trauma Violence Abuse"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/J.CHIABU.2019.104082","article-title":"The association between five forms of child maltreatment and depressive and anxiety disorders: A systematic review and meta-analysis","volume":"96","author":"Gardner","year":"2019","journal-title":"Child Abuse Negl"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAPSYCHIATRY.2024.0039","article-title":"Adverse childhood experiences and adult mental health outcomes","volume":"81","author":"Dan\u00edelsd\u00f3ttir","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1353\/HPU.2019.0018","article-title":"Adverse childhood experiences and trust in the medical profession among young adults","volume":"30","author":"Munoz","year":"2019","journal-title":"J Health Care Poor Underserved"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/BMJPH-2023-000868","article-title":"Associations between adverse childhood experiences and trust in health and other information from public services, professionals and wider sources: national cross sectional survey","volume":"2","author":"Bellis","year":"2024","journal-title":"BMJ Public Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2022","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0020","article-title":"The therapeutic alliance in psychedelic-assisted psychotherapy: A novel target for research and interventions","volume":"1","author":"Kamilar-Britt","year":"2023","journal-title":"Psychedelic Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300501","article-title":"The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder","volume":"19","author":"Levin","year":"2024","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000546270","article-title":"In psychedelic-assisted therapy, the alliance in the psychotherapy component is as important as the drug","volume":"94","author":"Fl\u00fcckiger","year":"2025","journal-title":"Psychother Psychosom"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAD.2026.121662","article-title":"The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis","volume":"406","author":"Goodwin","year":"2026","journal-title":"J Affect Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1037\/h0085885","article-title":"The generalizability of the psychoanalytic concept of the working alliance","volume":"16","author":"Bordin","year":"1979","journal-title":"Psychotherapy: Theory Res Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.68.3.438","article-title":"Relation of the therapeutic alliance with outcome and other variables: A meta-analytic review","volume":"68","author":"Martin","year":"2000","journal-title":"J Consult Clin Psychol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2020.101921","article-title":"Therapeutic alliance as a mediator of change: A systematic review and evaluation of research","volume":"82","author":"Baier","year":"2020","journal-title":"Clin Psychol Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00363-2","article-title":"Treatment with psychedelics is psychotherapy: beyond reductionism","volume":"11","author":"Gr\u00fcnder","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06620-x","article-title":"Psychedelic-assisted psychotherapy: where is the psychotherapy research","volume":"241","author":"Aday","year":"2024","journal-title":"Psychopharmacol (Berl)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2024.2410853","article-title":"Psychedelic therapy \u2013 refining the claim of a paradigm shift","volume":"36","author":"Aicher","year":"2024","journal-title":"Int Rev Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1176\/APPI.AJP.20221043","article-title":"Must psilocybin always \u201cassist psychotherapy\u201d","volume":"181","author":"Goodwin","year":"2024","journal-title":"Am J Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1176\/APPI.AJP.20230661","article-title":"Misinterpretations and omissions: A critical response to Goodwin and colleagues\u2019 commentary on psilocybin-assisted therapy","volume":"181","author":"O\u2019Donnell","year":"2024","journal-title":"Am J Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1511\/2025.113.3.170","article-title":"Psychedelics move toward mainstream medicine","volume":"113","author":"Nemeroff","year":"2025","journal-title":"Am Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.10.016","article-title":"The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis","volume":"369","author":"Li","year":"2025","journal-title":"J Affect Disord"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1176\/APPI.AJP.20230667","article-title":"Psychedelic assisted therapy\u201d must not be retired","volume":"181","author":"Deckel","year":"2024","journal-title":"Am J Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120637","article-title":"Pharmacodynamic biomarker \u2014 or psychotherapeutic process? Comment on \u201cThe role of the psychedelic experience in psilocybin treatment for treatment-resistant depression","volume":"394","author":"Wolff","year":"2026","journal-title":"J Affect Disord"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1177\/20503245251348272","article-title":"Reframing psychedelic regulation: Tools, not treatments","volume":"11","author":"Wolff","year":"2025","journal-title":"Drug Sci Policy Law"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1177\/20451253251381074","article-title":"Psychedelic-assisted therapy as a complex intervention: Implications for clinical trial design","volume":"15","author":"Muthumaraswamy","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/EURPUB\/CKR084","article-title":"When are complex interventions \u2018complex\u2019? When are simple interventions \u2018simple\u2019","volume":"21","author":"Petticrew","year":"2011","journal-title":"Eur J Public Health"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00748-y","article-title":"Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies","volume":"34","author":"Breeksema","year":"2020","journal-title":"CNS Drugs"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S432537","article-title":"Trauma-informed care in psychedelic therapy research: A qualitative literature review of evidence-based psychotherapy interventions in PTSD and psychedelic therapy across conditions","volume":"20","author":"Modlin","year":"2024","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/inm.13127","article-title":"Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis","volume":"32","author":"Crowe","year":"2023","journal-title":"Int J Ment Health Nurs"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.35024","article-title":"Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis","volume":"130","author":"Beaussant","year":"2024","journal-title":"Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/28314425251394012","article-title":"Qualitative research on psilocybin-assisted psychotherapy for the treatment of mental disorders: A scoping review","volume":"4","author":"Pincombe","year":"2025","journal-title":"Psychedelic Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J Humanist Psychol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103692","article-title":"Investigational psilocybin treatment for post-traumatic stress disorder: A qualitative study of participant experience, trauma engagement, and differences from standard treatment","volume":"90","author":"Modlin","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts","volume":"32","author":"Noorani","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1177\/0022167817706884","article-title":"Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis","volume":"57","author":"Belser","year":"2017","journal-title":"J Hum Psychol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1177\/0022167817715966","article-title":"Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress","volume":"57","author":"Swift","year":"2017","journal-title":"J Humanist Psychol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1177\/00221678211022949","article-title":"Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis","volume":"64","author":"Agin-Liebes","year":"2024","journal-title":"J Humanist Psychol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1037\/adb0000935","article-title":"Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis","volume":"38","author":"Agin-Liebes","year":"2024","journal-title":"Psychol Addictive Behav"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00256","article-title":"Individual experiences in four cancer patients following psilocybin-assisted psychotherapy","volume":"9","author":"Malone","year":"2018","journal-title":"Front Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/S12152-023-09536-Z","article-title":"When the trial ends: The case for post-trial provisions in clinical psychedelic research","volume":"17","author":"Jacobs","year":"2024","journal-title":"Neuroethics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/PSYMED.2024.0027","article-title":"Participants\u2019 experience of psychedelic integration groups and processes: A qualitative thematic analysis","volume":"3","author":"Modlin","year":"2025","journal-title":"Psychedelic Med (New Rochelle NY)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/09540261.2024.2357678","article-title":"Psychedelic group-based integration: Ethical assessment and initial recommendations","volume":"36","author":"Cheung","year":"2024","journal-title":"Int Rev Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/14780887.2017.1282567","article-title":"Advocacy processes in mental health: A qualitative study","volume":"14","author":"Stomski","year":"2017","journal-title":"Qual Res Psychol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEDT.2022.105324","article-title":"Understanding the impact of expert by experience roles in mental health education","volume":"111","author":"Happell","year":"2022","journal-title":"Nurse Educ Today"},{"key":"B76","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s44220-023-00040-0","article-title":"Lived experience: Shifting focus","volume":"1","author":"Redit","year":"2023","journal-title":"Nat Ment Health"},{"key":"B77","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1192\/BJB.2021.51","article-title":"Perspectives: Involving persons with lived experience of mental health conditions in service delivery, development and leadership","volume":"46","author":"Sunkel","year":"2022","journal-title":"BJPsych Bull"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1743598","article-title":"We are ambassadors, we are advocates\u201d: Rare disease patient advocacy groups as knowledge brokers across health and social systems\u2014a qualitative study from Poland","volume":"14","author":"Domaradzki","year":"2026","journal-title":"Front Public Health"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2333393617742282","DOI":"10.1177\/2333393617742282","article-title":"Employing a qualitative description approach in health care research","volume":"4","author":"Bradshaw","year":"2017","journal-title":"Glob Qual Nurs Res"},{"key":"B80","first-page":"218","article-title":"Spotlight on focus groups","volume":"55","author":"Leung","year":"2009","journal-title":"Can Fam Physician"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5958\/2249-5223.2016.00001.2","article-title":"Focus group discussion in qualitative research","volume":"6","author":"Mishra","year":"2016","journal-title":"TechnoLearn: Int J Educ Technol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/J.SAPHARM.2025.05.013","article-title":"Reclaiming dialogue: Focus groups and hermeneutic phenomenology","volume":"21","author":"Vella","year":"2025","journal-title":"Res Soc Administrative Pharm"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/2159676X.2019.1628806","article-title":"Reflecting on reflexive thematic analysis","volume":"11","author":"Braun","year":"2019","journal-title":"Qual Res Sport Exerc Health"},{"key":"B84","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/14780887.2020.1769238","article-title":"One size fits all? What counts as quality practice in (reflexive) thematic analysis","volume":"18","author":"Braun","year":"2021","journal-title":"Qual Res Psychol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14780887.2024.2382244","article-title":"Reporting guidelines for qualitative research: A values-based approach","volume":"22","author":"Braun","year":"2025","journal-title":"Qual Res Psychol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1177\/02692163241234800","article-title":"Supporting best practice in reflexive thematic analysis reporting in Palliative Medicine: A review of published research and introduction to the Reflexive Thematic Analysis Reporting Guidelines (RTARG)","volume":"38","author":"Braun","year":"2024","journal-title":"Palliat Med"},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.4135\/9781412984287","volume-title":"Focus Groups as Qualitative Research","author":"L.Morgan","year":"1997"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.4135\/9781526441836","volume-title":"Doing Focus Groups","author":"Barbour","year":"2018"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/INTQHC\/MZM042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J For Qual Health Care"},{"key":"B91","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/WPS.21056","article-title":"The future of psychopharmacology: A critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents","volume":"22","author":"Correll","year":"2023","journal-title":"World Psychiatry"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-019-1476-5","article-title":"The research burden of randomized controlled trial participation: A systematic thematic synthesis of qualitative evidence","volume":"18","author":"Naidoo","year":"2020","journal-title":"BMC Med 2020 18:1"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPSYCHIRES.2024.12.021","article-title":"The phenomenon of despair in patients with depression","volume":"181","author":"Mavrogiorgou","year":"2025","journal-title":"J Psychiatr Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development","volume":"9","author":"Schenberg","year":"2018","journal-title":"Front Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/CPT.557","article-title":"Psychedelics as medicines: An emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/PSYCHOACTIVES3020014","article-title":"Mind the psychedelic hype: Characterizing the risks and benefits of psychedelics for depression","volume":"3","author":"Meling","year":"2024","journal-title":"Psychoactives"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/J.BPSC.2024.02.004","article-title":"Expectancy effects in psychedelic trials","volume":"9","author":"Szigeti","year":"2024","journal-title":"Biol Psychiatry Cognit Neurosci Neuroimaging"},{"key":"B99","unstructured":"Psychedelic clinical trials and the Michael Pollan effect\n          \n          \n          Psychedelic Spotlight\n          \n          2026"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: From anecdotes and misinformation to systematic science","volume":"36","author":"Schlag","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.17179\/excli2024-8023","article-title":"Psychedelic-assisted therapy - supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics","volume":"23","author":"Tang","year":"2024","journal-title":"EXCLI J"},{"key":"B102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2307\/3563957","article-title":"Respondent burden in clinical research: When are we asking too much of subjects","volume":"27","author":"Ulrich","year":"2005","journal-title":"IRB"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/S00213-022-06221-6","article-title":"Expectancy in placebo-controlled trials of psychedelics: If so, so what","volume":"239","author":"Butler","year":"2022","journal-title":"Psychopharmacol (Berl)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JAD.2023.02.030","article-title":"Unblinding and demand characteristics in the treatment of depression","volume":"328","author":"Goodwin","year":"2023","journal-title":"J Affect Disord"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1017\/S0033291723001289","article-title":"Dark loops: Contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials","volume":"53","author":"Noorani","year":"2023","journal-title":"Psychol Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(99)00141-9","article-title":"Barriers to participation in randomised controlled trials: A systematic review","volume":"52","author":"Ross","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3193","article-title":"Patients\u2019 roles and rights in research","volume":"362","author":"Wicks","year":"2018","journal-title":"BMJ"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12805","article-title":"Patient and public involvement in the design of clinical trials: An overview of systematic reviews","volume":"24","author":"Price","year":"2018","journal-title":"J Eval Clin Pract"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2969","article-title":"Global public attitudes about clinical research and patient experiences with clinical trials","volume":"1","author":"Anderson","year":"2018","journal-title":"JAMA Netw Open"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.4c00279","article-title":"Psilocybin facilitates fear extinction: Importance of dose, context, and serotonin receptors","volume":"15","author":"Woodburn","year":"2024","journal-title":"ACS Chem Neurosci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcbs.2019.10.003","article-title":"Toward a contextual psychedelic-assisted therapy: Perspectives from acceptance and commitment therapy and contextual behavioral science","volume":"14","author":"Luoma","year":"2019","journal-title":"J Context Behav Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"00221678221081380","DOI":"10.1177\/00221678221081380","article-title":"Presence, trust, and empathy: Preferred characteristics of psychedelic carers","author":"Thal","year":"2022","journal-title":"J Humanist Psychol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to let go: A cognitive-behavioral model of how psychedelic therapy promotes acceptance","volume":"11","author":"Wolff","year":"2020","journal-title":"Front Psychiatr"},{"key":"B116","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/10503300500469098","article-title":"Principles for facilitating agency in psychotherapy","volume":"17","author":"Williams","year":"2007","journal-title":"Psychother Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jad.2023.01.077","article-title":"Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation","volume":"326","author":"Modlin","year":"2023","journal-title":"J Affect Disord"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221127954","article-title":"Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy\u2014A systematized review","volume":"36","author":"Thal","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1038\/S41598-024-53829-Z","article-title":"Development and psychometric validation of a novel scale for measuring \u2018psychedelic preparedness\u2019","volume":"14","author":"McAlpine","year":"2024","journal-title":"Sci Rep"},{"key":"B120","doi-asserted-by":"publisher","first-page":"28817","DOI":"10.1038\/S41598-024-79931-W","article-title":"Strategies for resolving challenging psychedelic experiences: Insights from a mixed-methods study","volume":"14","author":"Wood","year":"2024","journal-title":"Sci Rep"},{"key":"B121","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/15265161.2024.2433428","article-title":"Supportive touch in psychedelic assisted therapy","volume":"25","author":"Neitzke-Spruill","year":"2025","journal-title":"Am J Bioethics"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2024.2433437","article-title":"Holding without touch: Supportive touch in psychedelic-assisted psychotherapy","volume":"25","author":"Insua-Summerhays","year":"2025","journal-title":"Am J Bioethics"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2024.2433425","article-title":"From theory to practice: The importance of operationalizing and measuring ethical touch in psychedelic-assisted therapy","volume":"25","author":"Luoma","year":"2025","journal-title":"Am J Bioethics"},{"key":"B124","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.neubiorev.2022.104793","article-title":"Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review","volume":"140","author":"van Elk","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYG.2022.824077","article-title":"Psychedelic integration: An analysis of the concept and its practice","volume":"13","author":"Bathje","year":"2022","journal-title":"Front Psychol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2022.00232","article-title":"Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands","volume":"6","author":"Lutkajtis","year":"2023","journal-title":"J Psychedelic Stud"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1037\/PHA0000684","article-title":"Call for evidence-based psychedelic integration","volume":"32","author":"Gre\u0144","year":"2023","journal-title":"Exp Clin Psychopharmacol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1054692","article-title":"Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists","volume":"14","author":"Gre\u0144","year":"2023","journal-title":"Front Psychol"},{"key":"B129","unstructured":"Knox\n              J\n            \n          \n          Self-agency in psychotherapy: Attachment, autonomy, and intimacy\n          \n          2011"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1682810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:20:27Z","timestamp":1791958827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1682810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":129,"alternative-id":["10.3389\/fpsyt.2026.1682810"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1682810","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"article-number":"1682810"}}